Literature DB >> 26531759

Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.

J E Ryan1,2,3, S K Warrier1, A C Lynch1, R G Ramsay4,5, W A Phillips5,6, A G Heriot1.   

Abstract

AIM: Approximately 20% of patients treated with neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer achieve a pathological complete response (pCR) while the remainder derive the benefit of improved local control and downstaging and a small proportion show a minimal response. The ability to predict which patients will benefit would allow for improved patient stratification directing therapy to those who are likely to achieve a good response, thereby avoiding ineffective treatment in those unlikely to benefit.
METHOD: A systematic review of the English language literature was conducted to identify pathological factors, imaging modalities and molecular factors that predict pCR following chemoradiotherapy. PubMed, MEDLINE and Cochrane Database searches were conducted with the following keywords and MeSH search terms: 'rectal neoplasm', 'response', 'neoadjuvant', 'preoperative chemoradiation', 'tumor response'. After review of title and abstracts, 85 articles addressing the prediction of pCR were selected.
RESULTS: Clear methods to predict pCR before chemoradiotherapy have not been defined. Clinical and radiological features of the primary cancer have limited ability to predict response. Molecular profiling holds the greatest potential to predict pCR but adoption of this technology will require greater concordance between cohorts for the biomarkers currently under investigation.
CONCLUSION: At present no robust markers of the prediction of pCR have been identified and the topic remains an area for future research. This review critically evaluates existing literature providing an overview of the methods currently available to predict pCR to nCRT for locally advanced rectal cancer. The review also provides a comprehensive comparison of the accuracy of each modality. Colorectal Disease
© 2015 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Rectal cancer; pathologic complete response; prediction

Mesh:

Substances:

Year:  2016        PMID: 26531759     DOI: 10.1111/codi.13207

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  44 in total

Review 1.  [Evidence-based surgery of rectal cancer].

Authors:  M Grade; H Flebbe; B M Ghadimi
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

2.  Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer.

Authors:  Yuan Cheng; Yahong Luo; Yue Hu; Zhaohe Zhang; Xingling Wang; Qing Yu; Guanyu Liu; Enuo Cui; Tao Yu; Xiran Jiang
Journal:  Abdom Radiol (NY)       Date:  2021-07-24

Review 3.  Genetics of rectal cancer and novel therapies: primer for radiologists.

Authors:  Sebastian Mondaca; Rona Yaeger
Journal:  Abdom Radiol (NY)       Date:  2019-11

4.  FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.

Authors:  Pierre Lovinfosse; Marc Polus; Daniel Van Daele; Philippe Martinive; Frédéric Daenen; Mathieu Hatt; Dimitris Visvikis; Benjamin Koopmansch; Frédéric Lambert; Carla Coimbra; Laurence Seidel; Adelin Albert; Philippe Delvenne; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-18       Impact factor: 9.236

5.  Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma.

Authors:  M L Sánchez de Molina; C Díaz Del Arco; P Vorwald; D García-Olmo; L Estrada; M J Fernández-Aceñero
Journal:  Clin Transl Oncol       Date:  2017-06-26       Impact factor: 3.405

6.  Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.

Authors:  AnnaLee Policicchio; Joey Mercier; Antonia Digklia; Ioannis A Voutsadakis
Journal:  J Gastrointest Cancer       Date:  2019-12

7.  Ratio of Pathological Response to Preoperative Chemotherapy in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer Correlates with Survival.

Authors:  Eyal Mor; Dan Assaf; Shachar Laks; Haggai Benvenisti; Gal Schtrechman; David Hazzan; Lior Segev; Ronel Yaka; Einat Shacham-Shmueli; Ofer Margalit; Naama Halpern; Daria Perelson; Monica-Inda Kaufmann; Almog Ben-Yaacov; Aviram Nissan; Mohammad Adileh
Journal:  Ann Surg Oncol       Date:  2021-07-07       Impact factor: 5.344

8.  Development of a Joint Prediction Model Based on Both the Radiomics and Clinical Factors for Predicting the Tumor Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer.

Authors:  Yang Liu; Feng-Jiao Zhang; Xi-Xi Zhao; Yuan Yang; Chun-Yi Liang; Li-Li Feng; Xiang-Bo Wan; Yi Ding; Yao-Wei Zhang
Journal:  Cancer Manag Res       Date:  2021-04-13       Impact factor: 3.989

9.  Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy.

Authors:  Jung Il Joo; Sang Woo Lim; Bo Young Oh
Journal:  Ann Coloproctol       Date:  2021-05-11

10.  Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies.

Authors:  Michael A Gillespie; Colin W Steele; Tamsin R M Lannagan; Owen J Sansom; Campbell S D Roxburgh
Journal:  Oncol Rev       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.